Literature DB >> 24396255

Erythropoietin has a restorative effect on the contractility of arteries following experimental hypoxia.

Sarah B Withers1, Neha Passi1, Alfred S Williams1, Declan de Freitas2, Anthony M Heagerty1.   

Abstract

INTRODUCTION: The aim of this study was to investigate the effect of erythropoietin on vascular contractility using an in vitro model of hypoxia replicating the hypoxic environment of blood vessels and surrounding adipose tissue in obesity. METHODS AND
RESULTS: Pharmacological in vitro studies were carried out on small mesenteric arterial segments from male Wistar rats with and without perivascular fat and endothelium. Contractile responses were investigated by wire myography under normoxia, experimental hypoxia ± erythropoietin and l-NNA. Perivascular fat exerted an anticontractile effect which was lost following the induction of experimental hypoxia. Erythropoietin prevented the loss of the anticontractile capacity when vessels were incubated for one hour before the induction of hypoxia or throughout the period of hypoxia; this was found to be independent of the function of perivascular fat, as fat denuded arteries had a similar reduction in contractility (artery no fat + hypoxia vs. artery no fat + hypoxia + erythropoietin). The mechanism by which erythropoietin was exerting its effect was found to be partially endothelium dependent and associated with an increase of nitric oxide bioavailability as nitric oxide synthase inhibition prevented the effect.
CONCLUSIONS: Whilst erythropoietin is working downstream from perivascular fat, it is possible that it may be therapeutically useful in obesity when hypoxia and inflammation reduce the normal activity of perivascular fat.

Entities:  

Keywords:  ACh, acetylcholine; BMI, body mass index; CKD, chronic kidney disease; EPO, erythropoietin; KPSS, high potassium physiological salt solution; LDL, low density lipoproteins; Microcirculation; Myograph; NA, noradrenaline; NO, nitric oxide; Obesity; PSS, physiological salt solution; SEM, standard error of the mean; eNOS, endothelial nitric oxide synthase; l-NNA, Nω-nitro-l-arginine

Year:  2013        PMID: 24396255      PMCID: PMC3849290          DOI: 10.1016/j.jcdr.2013.08.002

Source DB:  PubMed          Journal:  J Cardiovasc Dis Res        ISSN: 0975-3583


  40 in total

1.  Prevention Conference VII: Obesity, a worldwide epidemic related to heart disease and stroke: executive summary.

Authors:  Robert H Eckel; David A York; Stephan Rössner; Van Hubbard; Ian Caterson; Sachiko T St Jeor; Laura L Hayman; Rebecca M Mullis; Steven N Blair
Journal:  Circulation       Date:  2004-11-02       Impact factor: 29.690

Review 2.  The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences.

Authors:  Sarah de Ferranti; Dariush Mozaffarian
Journal:  Clin Chem       Date:  2008-04-24       Impact factor: 8.327

Review 3.  Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise.

Authors:  M Brines; A Cerami
Journal:  Kidney Int       Date:  2006-05-31       Impact factor: 10.612

4.  Essential role of endothelial nitric oxide synthase in vascular effects of erythropoietin.

Authors:  Livius V d'Uscio; Leslie A Smith; Anantha V Santhanam; Darcy Richardson; Karl A Nath; Zvonimir S Katusic
Journal:  Hypertension       Date:  2007-03-19       Impact factor: 10.190

5.  Predictors of end-stage renal disease and body mass index in a screened cohort.

Authors:  K Iseki; Y Ikemiya; K Fukiyama
Journal:  Kidney Int Suppl       Date:  1997-12       Impact factor: 10.545

6.  Modulation of vascular function by perivascular adipose tissue: the role of endothelium and hydrogen peroxide.

Authors:  Y-J Gao; C Lu; L-Y Su; A M Sharma; R M K W Lee
Journal:  Br J Pharmacol       Date:  2007-03-26       Impact factor: 8.739

7.  Serum resistin as a novel marker of erythropoietin resistance in nondiabetic patients on hemodialysis.

Authors:  Jae Hyun Chang; Ji Yong Jung; Hyun Hee Lee; Wookyung Chung; Kwon-Wook Joo; Sejoong Kim
Journal:  Tohoku J Exp Med       Date:  2011-08       Impact factor: 1.848

8.  Influence of long-term recombinant human erythropoietin (rHuEpo) therapy on plasma leptin and neuropeptide Y concentration in haemodialysed uraemic patients.

Authors:  F Kokot; A Wiecek; J Mesjasz; M Adamczak; U Spiechowicz
Journal:  Nephrol Dial Transplant       Date:  1998-05       Impact factor: 5.992

Review 9.  Erythropoietin in heart and vessels: focus on transcription and signalling pathways.

Authors:  Francesca Marzo; Alberto Lavorgna; Giulio Coluzzi; Eleonora Santucci; Federica Tarantino; Teresa Rio; Elena Conti; Camillo Autore; Luciano Agati; Felicita Andreotti
Journal:  J Thromb Thrombolysis       Date:  2008-03-13       Impact factor: 2.300

10.  Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis.

Authors:  C G Winearls; D O Oliver; M J Pippard; C Reid; M R Downing; P M Cotes
Journal:  Lancet       Date:  1986-11-22       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.